Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143403 | 0.78 | HTR6 (0.49) | ALDH1A1POLBTSPOSIRT2C5AR1 | |
| SCHEMBL14349335 | 0.74 | ALOX15 (0.46) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL17871133 | 0.72 | FSCN1 (0.54) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL14349387 | 0.72 | FSCN1 (0.49) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL31050253 | 0.70 | FSCN1 (0.40) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL20590388 | 0.68 | HSD11B1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL31050364 | 0.66 | SMN1; SMN2 (0.46) | ALDH1A1BRD4HTTTSHR | |
| SCHEMBL2378380 | 0.65 | MTNR1A (0.48) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL23609755 | 0.65 | NR4A2 (0.46) | FSCN1ALDH1A1LMNAPOLBBRD4 | |
| SCHEMBL16896762 | 0.64 | TSPO (0.47) | FSCN1ALDH1A1TSPOTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024169952-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376105-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | FSCN1 4131/4885ALDH1A1 2171/4885LMNA 3104/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | FSCN1 4131/4885ALDH1A1 2171/4885LMNA 3104/4885 |
| US-20240327404-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | FSCN1 4131/4885ALDH1A1 2171/4885LMNA 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.